Novo Nordisk didn’t let the pandemic scupper the launch of its oral diabetes drug Rybelsus last year. Now, with strong sales on the docket, it’s pledging millions to expand future capacity for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback